MovDisordV3, PascalFrancis, Corpus, bibRecord, 001261

Validation of the "QUICK" Questionnaire : A Tool for Diagnosis of "Wearing-Off" in Patients with Parkinson's Disease

Identifieur interne : 001261 ( PascalFrancis/Corpus ); précédent : 001260; suivant : 001262

Validation of the "QUICK" Questionnaire : A Tool for Diagnosis of "Wearing-Off" in Patients with Parkinson's Disease

Auteurs : Pablo Martinez-Martin ; Eduardo Tolosa ; Basilio Hernandez ; Xavier Badia

Source :

Movement disorders [ 0885-3185 ] ; 2008.

RBID : Pascal:08-0251872

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Validation, Questionnaire, Diagnostic, Homme, Dépistage, Validité.

English descriptors

KwdEn :
- Diagnosis, Human, Medical screening, Nervous system diseases, Parkinson disease, Questionnaire, Validation, Validity.

Abstract

: The main objective of the present study was to test the validity of a 19-items instrument (QUICK Questionnaire, QQ) as a tool for screening of WO. Two hundred twenty-two patients (36.0% without WO; 64.0% with mild or moderate/ severe WO) were included. Diagnosis of WO by the participant neurologist was considered the "gold standard." The complete Unified Parkinson's Disease Rating Scale battery, the Cumulative Illness Rating Scale-Geriatrics, and a form about WO presence and severity were completed by the neurologist. Patients independently completed the QQ just before the clinical assessment. As a whole, patients with WO were more disabled than patients without and patients with moderate/severe WO were in worse condition than patients with mild WO. The number of QQ symptoms declared to improve usually after the following dose of medication was 1.0 ± 1.8 in the group without WO, but 6.0 ± 3.8 in patients with WO (P < 0.001). A two QQ positive symptoms cut-off showed the following attributes: sensitivity, 88%; specificity, 80%; positive predictive value, 88.7%; negative predictive value, 79%; diagnostic accuracy, 85%; positive and negative likelihood ratios 4.4 and 0.15, respectively. The area under the ROC curve resulted 0.90 (CI95%: 0.86-0.94%). In summary, the QQ proved to be a valid screening tool to identify WO in PD patients. To our knowledge, the QQ is the only validated tool for diagnosis of WO.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 23`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Validation of the "QUICK" Questionnaire : A Tool for Diagnosis of "Wearing-Off" in Patients with Parkinson's Disease`
A11	`01`	`1`		`@1 MARTINEZ-MARTIN (Pablo)`
A11	`02`	`1`		`@1 TOLOSA (Eduardo)`
A11	`03`	`1`		`@1 HERNANDEZ (Basilio)`
A11	`04`	`1`		`@1 BADIA (Xavier)`
A14	`01`			`@1 Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III, Institute of Health @2 Madrid @3 ESP @Z 1 aut.`
A14	`02`			`@1 Centro de Investigación Biomédica en Red sobre Enfermedades, Neurodegenerativas (CIBERNED) @2 Madrid @3 ESP @Z 1 aut.`
A14	`03`			`@1 Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut, Clinic de Neurociències, Hospital Clinic de Barcelona, Universitat de Barcelona, IDIBAPS @2 Barcelona @3 ESP @Z 2 aut.`
A14	`04`			`@1 Centro de Investigación Biomédica en Red sobre Enfermedades, Neurodegenerativas (CIBERNED) @2 Barcelona @3 ESP @Z 2 aut.`
A14	`05`			`@1 Medical Department, Novartis Farmaceutica, SA @2 Barcelona @3 ESP @Z 3 aut.`
A14	`06`			`@1 IMS Health @2 Barcelona @3 ESP @Z 4 aut.`
A17	`01`	`1`		`@1 ValidQUICK Study Group @3 ESP`
A20				`@1 830-836`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000195888140090`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 20 ref.`
A47	`01`	`1`		`@0 08-0251872`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 : The main objective of the present study was to test the validity of a 19-items instrument (QUICK Questionnaire, QQ) as a tool for screening of WO. Two hundred twenty-two patients (36.0% without WO; 64.0% with mild or moderate/ severe WO) were included. Diagnosis of WO by the participant neurologist was considered the "gold standard." The complete Unified Parkinson's Disease Rating Scale battery, the Cumulative Illness Rating Scale-Geriatrics, and a form about WO presence and severity were completed by the neurologist. Patients independently completed the QQ just before the clinical assessment. As a whole, patients with WO were more disabled than patients without and patients with moderate/severe WO were in worse condition than patients with mild WO. The number of QQ symptoms declared to improve usually after the following dose of medication was 1.0 ± 1.8 in the group without WO, but 6.0 ± 3.8 in patients with WO (P < 0.001). A two QQ positive symptoms cut-off showed the following attributes: sensitivity, 88%; specificity, 80%; positive predictive value, 88.7%; negative predictive value, 79%; diagnostic accuracy, 85%; positive and negative likelihood ratios 4.4 and 0.15, respectively. The area under the ROC curve resulted 0.90 (CI95%: 0.86-0.94%). In summary, the QQ proved to be a valid screening tool to identify WO in PD patients. To our knowledge, the QQ is the only validated tool for diagnosis of WO.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Validation @5 09`
C03	`03`	`X`	`ENG`	`@0 Validation @5 09`
C03	`03`	`X`	`SPA`	`@0 Validación @5 09`
C03	`04`	`X`	`FRE`	`@0 Questionnaire @5 10`
C03	`04`	`X`	`ENG`	`@0 Questionnaire @5 10`
C03	`04`	`X`	`SPA`	`@0 Cuestionario @5 10`
C03	`05`	`X`	`FRE`	`@0 Diagnostic @5 11`
C03	`05`	`X`	`ENG`	`@0 Diagnosis @5 11`
C03	`05`	`X`	`SPA`	`@0 Diagnóstico @5 11`
C03	`06`	`X`	`FRE`	`@0 Homme @5 12`
C03	`06`	`X`	`ENG`	`@0 Human @5 12`
C03	`06`	`X`	`SPA`	`@0 Hombre @5 12`
C03	`07`	`X`	`FRE`	`@0 Dépistage @5 13`
C03	`07`	`X`	`ENG`	`@0 Medical screening @5 13`
C03	`07`	`X`	`SPA`	`@0 Descubrimiento @5 13`
C03	`08`	`X`	`FRE`	`@0 Validité @5 14`
C03	`08`	`X`	`ENG`	`@0 Validity @5 14`
C03	`08`	`X`	`SPA`	`@0 Validez @5 14`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 162`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 08-0251872 INIST
ET :	Validation of the "QUICK" Questionnaire : A Tool for Diagnosis of "Wearing-Off" in Patients with Parkinson's Disease
AU :	MARTINEZ-MARTIN (Pablo); TOLOSA (Eduardo); HERNANDEZ (Basilio); BADIA (Xavier)
AF :	Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III, Institute of Health/Madrid/Espagne (1 aut.); Centro de Investigación Biomédica en Red sobre Enfermedades, Neurodegenerativas (CIBERNED)/Madrid/Espagne (1 aut.); Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut, Clinic de Neurociències, Hospital Clinic de Barcelona, Universitat de Barcelona, IDIBAPS/Barcelona/Espagne (2 aut.); Centro de Investigación Biomédica en Red sobre Enfermedades, Neurodegenerativas (CIBERNED)/Barcelona/Espagne (2 aut.); Medical Department, Novartis Farmaceutica, SA/Barcelona/Espagne (3 aut.); IMS Health/Barcelona/Espagne (4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 6; Pp. 830-836; Bibl. 20 ref.
LA :	Anglais
EA :	: The main objective of the present study was to test the validity of a 19-items instrument (QUICK Questionnaire, QQ) as a tool for screening of WO. Two hundred twenty-two patients (36.0% without WO; 64.0% with mild or moderate/ severe WO) were included. Diagnosis of WO by the participant neurologist was considered the "gold standard." The complete Unified Parkinson's Disease Rating Scale battery, the Cumulative Illness Rating Scale-Geriatrics, and a form about WO presence and severity were completed by the neurologist. Patients independently completed the QQ just before the clinical assessment. As a whole, patients with WO were more disabled than patients without and patients with moderate/severe WO were in worse condition than patients with mild WO. The number of QQ symptoms declared to improve usually after the following dose of medication was 1.0 ± 1.8 in the group without WO, but 6.0 ± 3.8 in patients with WO (P < 0.001). A two QQ positive symptoms cut-off showed the following attributes: sensitivity, 88%; specificity, 80%; positive predictive value, 88.7%; negative predictive value, 79%; diagnostic accuracy, 85%; positive and negative likelihood ratios 4.4 and 0.15, respectively. The area under the ROC curve resulted 0.90 (CI95%: 0.86-0.94%). In summary, the QQ proved to be a valid screening tool to identify WO in PD patients. To our knowledge, the QQ is the only validated tool for diagnosis of WO.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Pathologie du système nerveux; Validation; Questionnaire; Diagnostic; Homme; Dépistage; Validité
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Parkinson disease; Nervous system diseases; Validation; Questionnaire; Diagnosis; Human; Medical screening; Validity
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Parkinson enfermedad; Sistema nervioso patología; Validación; Cuestionario; Diagnóstico; Hombre; Descubrimiento; Validez
LO :	INIST-20953.354000195888140090
ID :	08-0251872

Links to Exploration step

Pascal:08-0251872

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Validation of the "QUICK" Questionnaire : A Tool for Diagnosis of "Wearing-Off" in Patients with Parkinson's Disease</title>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation><inist:fA14 i1="01"><s1>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III, Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Centro de Investigación Biomédica en Red sobre Enfermedades, Neurodegenerativas (CIBERNED)</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name>
<affiliation><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut, Clinic de Neurociències, Hospital Clinic de Barcelona, Universitat de Barcelona, IDIBAPS</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Centro de Investigación Biomédica en Red sobre Enfermedades, Neurodegenerativas (CIBERNED)</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hernandez, Basilio" sort="Hernandez, Basilio" uniqKey="Hernandez B" first="Basilio" last="Hernandez">Basilio Hernandez</name>
<affiliation><inist:fA14 i1="05"><s1>Medical Department, Novartis Farmaceutica, SA</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Badia, Xavier" sort="Badia, Xavier" uniqKey="Badia X" first="Xavier" last="Badia">Xavier Badia</name>
<affiliation><inist:fA14 i1="06"><s1>IMS Health</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0251872</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0251872 INIST</idno>
<idno type="RBID">Pascal:08-0251872</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001261</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Validation of the "QUICK" Questionnaire : A Tool for Diagnosis of "Wearing-Off" in Patients with Parkinson's Disease</title>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation><inist:fA14 i1="01"><s1>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III, Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Centro de Investigación Biomédica en Red sobre Enfermedades, Neurodegenerativas (CIBERNED)</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name>
<affiliation><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut, Clinic de Neurociències, Hospital Clinic de Barcelona, Universitat de Barcelona, IDIBAPS</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Centro de Investigación Biomédica en Red sobre Enfermedades, Neurodegenerativas (CIBERNED)</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hernandez, Basilio" sort="Hernandez, Basilio" uniqKey="Hernandez B" first="Basilio" last="Hernandez">Basilio Hernandez</name>
<affiliation><inist:fA14 i1="05"><s1>Medical Department, Novartis Farmaceutica, SA</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Badia, Xavier" sort="Badia, Xavier" uniqKey="Badia X" first="Xavier" last="Badia">Xavier Badia</name>
<affiliation><inist:fA14 i1="06"><s1>IMS Health</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Diagnosis</term>
<term>Human</term>
<term>Medical screening</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Questionnaire</term>
<term>Validation</term>
<term>Validity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Validation</term>
<term>Questionnaire</term>
<term>Diagnostic</term>
<term>Homme</term>
<term>Dépistage</term>
<term>Validité</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">: The main objective of the present study was to test the validity of a 19-items instrument (QUICK Questionnaire, QQ) as a tool for screening of WO. Two hundred twenty-two patients (36.0% without WO; 64.0% with mild or moderate/ severe WO) were included. Diagnosis of WO by the participant neurologist was considered the "gold standard." The complete Unified Parkinson's Disease Rating Scale battery, the Cumulative Illness Rating Scale-Geriatrics, and a form about WO presence and severity were completed by the neurologist. Patients independently completed the QQ just before the clinical assessment. As a whole, patients with WO were more disabled than patients without and patients with moderate/severe WO were in worse condition than patients with mild WO. The number of QQ symptoms declared to improve usually after the following dose of medication was 1.0 ± 1.8 in the group without WO, but 6.0 ± 3.8 in patients with WO (P < 0.001). A two QQ positive symptoms cut-off showed the following attributes: sensitivity, 88%; specificity, 80%; positive predictive value, 88.7%; negative predictive value, 79%; diagnostic accuracy, 85%; positive and negative likelihood ratios 4.4 and 0.15, respectively. The area under the ROC curve resulted 0.90 (CI95%: 0.86-0.94%). In summary, the QQ proved to be a valid screening tool to identify WO in PD patients. To our knowledge, the QQ is the only validated tool for diagnosis of WO.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>23</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Validation of the "QUICK" Questionnaire : A Tool for Diagnosis of "Wearing-Off" in Patients with Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MARTINEZ-MARTIN (Pablo)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>TOLOSA (Eduardo)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HERNANDEZ (Basilio)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BADIA (Xavier)</s1>
</fA11>
<fA14 i1="01"><s1>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III, Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Centro de Investigación Biomédica en Red sobre Enfermedades, Neurodegenerativas (CIBERNED)</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut, Clinic de Neurociències, Hospital Clinic de Barcelona, Universitat de Barcelona, IDIBAPS</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Centro de Investigación Biomédica en Red sobre Enfermedades, Neurodegenerativas (CIBERNED)</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Medical Department, Novartis Farmaceutica, SA</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>IMS Health</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>ValidQUICK Study Group</s1>
<s3>ESP</s3>
</fA17>
<fA20><s1>830-836</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000195888140090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>20 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0251872</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>: The main objective of the present study was to test the validity of a 19-items instrument (QUICK Questionnaire, QQ) as a tool for screening of WO. Two hundred twenty-two patients (36.0% without WO; 64.0% with mild or moderate/ severe WO) were included. Diagnosis of WO by the participant neurologist was considered the "gold standard." The complete Unified Parkinson's Disease Rating Scale battery, the Cumulative Illness Rating Scale-Geriatrics, and a form about WO presence and severity were completed by the neurologist. Patients independently completed the QQ just before the clinical assessment. As a whole, patients with WO were more disabled than patients without and patients with moderate/severe WO were in worse condition than patients with mild WO. The number of QQ symptoms declared to improve usually after the following dose of medication was 1.0 ± 1.8 in the group without WO, but 6.0 ± 3.8 in patients with WO (P < 0.001). A two QQ positive symptoms cut-off showed the following attributes: sensitivity, 88%; specificity, 80%; positive predictive value, 88.7%; negative predictive value, 79%; diagnostic accuracy, 85%; positive and negative likelihood ratios 4.4 and 0.15, respectively. The area under the ROC curve resulted 0.90 (CI95%: 0.86-0.94%). In summary, the QQ proved to be a valid screening tool to identify WO in PD patients. To our knowledge, the QQ is the only validated tool for diagnosis of WO.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Validation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Validation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Validación</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Questionnaire</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Questionnaire</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Cuestionario</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Diagnostic</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Diagnosis</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Diagnóstico</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Dépistage</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Medical screening</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Descubrimiento</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Validité</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Validity</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Validez</s0>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>162</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 08-0251872 INIST</NO>
<ET>Validation of the "QUICK" Questionnaire : A Tool for Diagnosis of "Wearing-Off" in Patients with Parkinson's Disease</ET>
<AU>MARTINEZ-MARTIN (Pablo); TOLOSA (Eduardo); HERNANDEZ (Basilio); BADIA (Xavier)</AU>
<AF>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III, Institute of Health/Madrid/Espagne (1 aut.); Centro de Investigación Biomédica en Red sobre Enfermedades, Neurodegenerativas (CIBERNED)/Madrid/Espagne (1 aut.); Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut, Clinic de Neurociències, Hospital Clinic de Barcelona, Universitat de Barcelona, IDIBAPS/Barcelona/Espagne (2 aut.); Centro de Investigación Biomédica en Red sobre Enfermedades, Neurodegenerativas (CIBERNED)/Barcelona/Espagne (2 aut.); Medical Department, Novartis Farmaceutica, SA/Barcelona/Espagne (3 aut.); IMS Health/Barcelona/Espagne (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 6; Pp. 830-836; Bibl. 20 ref.</SO>
<LA>Anglais</LA>
<EA>: The main objective of the present study was to test the validity of a 19-items instrument (QUICK Questionnaire, QQ) as a tool for screening of WO. Two hundred twenty-two patients (36.0% without WO; 64.0% with mild or moderate/ severe WO) were included. Diagnosis of WO by the participant neurologist was considered the "gold standard." The complete Unified Parkinson's Disease Rating Scale battery, the Cumulative Illness Rating Scale-Geriatrics, and a form about WO presence and severity were completed by the neurologist. Patients independently completed the QQ just before the clinical assessment. As a whole, patients with WO were more disabled than patients without and patients with moderate/severe WO were in worse condition than patients with mild WO. The number of QQ symptoms declared to improve usually after the following dose of medication was 1.0 ± 1.8 in the group without WO, but 6.0 ± 3.8 in patients with WO (P < 0.001). A two QQ positive symptoms cut-off showed the following attributes: sensitivity, 88%; specificity, 80%; positive predictive value, 88.7%; negative predictive value, 79%; diagnostic accuracy, 85%; positive and negative likelihood ratios 4.4 and 0.15, respectively. The area under the ROC curve resulted 0.90 (CI95%: 0.86-0.94%). In summary, the QQ proved to be a valid screening tool to identify WO in PD patients. To our knowledge, the QQ is the only validated tool for diagnosis of WO.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Pathologie du   système nerveux; Validation; Questionnaire; Diagnostic; Homme; Dépistage; Validité</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Parkinson disease; Nervous system diseases; Validation; Questionnaire; Diagnosis; Human; Medical screening; Validity</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Sistema nervioso patología; Validación; Cuestionario; Diagnóstico; Hombre; Descubrimiento; Validez</SD>
<LO>INIST-20953.354000195888140090</LO>
<ID>08-0251872</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001261 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001261 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:08-0251872
   |texte=   Validation of the "QUICK" Questionnaire : A Tool for Diagnosis of "Wearing-Off" in Patients with Parkinson's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Validation of the "QUICK" Questionnaire : A Tool for Diagnosis of "Wearing-Off" in Patients with Parkinson's Disease

Validation of the "QUICK" Questionnaire : A Tool for Diagnosis of "Wearing-Off" in Patients with Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri